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Abstract
Background: Ectopic pregnancy (EP) occurs in 1–2% of pregnancies, but is over-represented as a leading cause of maternal
death in early pregnancy. It remains a challenge to diagnose early and accurately. Women often present in early pregnancy
with a ‘pregnancy of unknown location’ (PUL) and the diagnosis and exclusion of EP is difficult due to a lack of reliable
biomarkers. A serum biomarker able to clearly distinguish between EP and other pregnancy outcomes would greatly assist
clinicians in diagnosing and safely managing PULs. This study evaluates the ability of maternal serum macrophage inhibitory
cytokine-1 (MIC-1) levels to differentiate between EP and other pregnancy outcomes in women with a PUL.
Methods: Sera were collected from 120 women with a PUL at first clinical presentation and assayed for MIC-1 by ELISA.
Results were classified according to ultimate pregnancy outcome and the discriminatory ability of MIC-1 to diagnose EP was
assessed.
Results: Serum MIC-1 levels were lower in women with histologically confirmed (definite) EP (dEP) (median 552 ng/mL;
interquartile range (IQR) 414–693 ng/mL) compared to women with definite viable intra-uterine pregnancies (dVIUPs)
(722 ng/mL; IQR 412–1122 ng/mL), and higher when compared to women with definite non-viable intra-uterine
pregnancies (dNVIUPs) (465 ng/mL; IQR 341–675 ng/mL). MIC-1 levels were significantly higher in women with dEP
compared to women whose PULs resolved without medical intervention (srPUL) (401 ng/mL; IQR 315–475 ng/mL)
(p,0.003). There were no women with an ectopic pregnancy where serum MIC-1.1000 ng/mL.
Conclusion: Serum MIC-1 levels in PUL were not able to categorically diagnose EP, however, MIC-1 could distinguish women
with an EP that required medical intervention and those women whose PULs spontaneously resolved. A single serum MIC-1
measurement also excluded EP at levels above 1000 ng/mL. MIC-1 may play a role in the development of a combined assay
of biomarkers for the diagnosis of EP.
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Introduction
Ectopic pregnancy (EP) occurs in 1–2% of pregnancies and
remains a leading cause of maternal death in early pregnancy
[1,2]. The most common symptoms of EP are abdominal pain
and/or vaginal bleeding, however, these are not specific to EP and
can be consistent with a range of pregnancy outcomes, including
on-going (definite) viable intrauterine pregnancies (dVIUPs) and
miscarriages (definite non-viable intrauterine pregnancies –
dNVIUPs). The challenge for the clinician is to be able to
accurately distinguish between pregnancy outcomes in order to
safely manage any woman presenting with these symptoms.
The diagnosis of EP relies on transvaginal ultrasonography
(TVUS), and three quarters of EPs will be diagnosed at the initial
scan (sensitivity of 73.9% and a specificity of 98.3%) [3]. When
neither an intrauterine nor an EP can be visualized by TVUS, the
woman is classified as having a pregnancy of unknown location
(PUL) [4]. This requires further time and resource intensive
follow-up, including serial serum human chorionic gonadotrophin
(hCG) levels and repeat TVUS to determine pregnancy location
and appropriate management [5,6]. Between 7–20% of women
with PUL are ultimately diagnosed with EP [7].
Recent research endeavour has focused on the potential for a
serum biomarker to be able to accurately diagnose EP at the time
of first presentation for women with PUL. A number of candidate
molecules have been proposed, but as single markers, none are
sufficiently discriminatory for diagnosing EP [8]. Some groups
have attempted combining serum biomarkers in tests with
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improved diagnostic accuracy, ranging from 52.9–98% sensitivity
and 92.4–100% specificity, however, these still require further
validation before potentially being used in a diagnostic algorithm
for EP [8].
Serum macrophage inhibitory cytokine-1 (MIC-1) is a divergent
member of the TGF-ß superfamily of cytokines, originally shown
to inhibit macrophages [9]. MIC-1 has been localized to the
syncytiotrophoblast and shown to increase in serum across the first
trimester of pregnancy [10], and is thought to increase the
population of tolerogenic dendritic cells in the decidua [11]. We
previously identified maternal serum concentrations of MIC-1 as a
potential predictive biomarker of miscarriage [12]. We then
validated this in a subsequent prospective cohort study of 782
women, which showed serum MIC-1 in early pregnancy to be
significantly lower in women who went on to miscarry [multiples
of the median (MOM) 0.63 (IQR 0.33–0.88) compared to women
with successful pregnancy outcomes (MOM 1.00 (IQR 0.76–1.29)
(p =,0.001), with an area under the curve (AUC) of 0.73 (95% CI
0.63–0.84) as a single biomarker predictor of miscarriage [13] ].
In this prospective cohort study, we assessed the ability of serum
MIC-1 levels to diagnose EP amongst women with PULs who
presented with abdominal pain and/or vaginal bleeding in early
pregnancy.
Results
We recruited 120 Caucasian women aged between 18–45 years
and diagnosed with a PUL after presentation with abdominal pain
and/or vaginal bleeding in early pregnancy. The outcomes of
these pregnancies were classified according to the recent PUL
consensus statement [4]. Table 1 details the definition and final
breakdown of pregnancy outcomes for the cohort, with no
differences demonstrated in their baseline characteristics (one-
way ANOVA).
Serum MIC-1 levels were lower in women with histologically
confirmed (definite) EP (dEP) (median 552 ng/mL; IQR 414–
693 ng/mL) compared to women with definite viable intrauterine
pregnancies (dVIUP) (722 ng/mL; IQR 412–1122 ng/mL), and
higher compared to women with definite non-viable intrauterine
pregnancies (dNVIUP) (465 ng/mL; IQR 341–675 ng/mL) and
treated PULs (tPUL) (400 ng/mL; IQR 388–473 ng/mL). Levels
were also higher in women with dEP than in women who were
medically managed for probable EPs (pEP) (434 ng/mL; IQR
315–541 ng/mL). Additionally, MIC-1 levels were significantly
higher in women with dEP compared to women with a PUL that
resolved spontaneously (i.e. without medical intervention) (srPUL)
(401 ng/mL; IQR 315–475 ng/mL) (p,0.003). Non-pregnant
(NP) women were included as a control and their serum MIC-1
levels were significantly lower than in women with dEP (330 ng/
mL; IQR 298–463 ng/mL) (p = 0.001) (Figure 1). Interestingly, a
correlation was observed between serum MIC-1 and serum hCG
levels in women with dVIUPs and dNVIUPs (Spearman; P,0.04
and P,0.03, respectively), but not in any other pregnancy
outcome categories (P.0.35).
ROC curve analysis suggests MIC-1 would have limited use in
the diagnosis of EP as a single biomarker (AUC=0.5547; p.0.4)
(Figure 2a). Removal of ambiguous PUL outcomes (srPUL, tPUL
and pEP) did not improve the performance of MIC-1 as a
biomarker of EP (AUC=0.5335; p.0.6) (Figure 2b), nor did
grouping pregnancy outcomes by those that required treatment
(dEP, pEP and tPUL) compared to those that did not (dNVIUP/
dVIUP/NP/srPUL) (AUC=0.5363; p.0.5) (Figure 2c). A single
serum MIC-1 measurement, however, excluded EP at levels above
1000 ng/mL (Figure 1) (positive predictive value (PPV) 100%,
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negative predictive value (NPV) 24%, sensitivity 17% and
specificity 100%; P,0.05).
Discussion
In this study, we demonstrated that serum MIC-1 measurement
has some potential as a diagnostic biomarker of EP in women with
a PUL. We prospectively recruited 120 women with an interim
diagnosis of PUL, who presented with symptoms of abdominal
pain and/or vaginal bleeding after a positive home pregnancy test.
Importantly, serum samples were collected at the time of first
presentation and not at the time of diagnosis, as would reflect true
clinical practice. We followed these women until complete
resolution of their pregnancies and classified their outcomes
according to the PUL consensus statement [4]. Whilst the number
of women in each pregnancy outcome category was relatively
small, the full range of PUL outcomes were represented in the
cohort. We additionally verified that previous exposure to C.
trachomatis did not influence MIC-1 levels in the sera of
participants. Hence this study robustly tests the potential of serum
MIC-1 levels as a biomarker of EP.
Although this study showed that a single serum MIC-1 level is
not sufficiently discriminatory to diagnose EP, serum MIC-1 level
measurement may help to exclude EP. No woman participating in
this study had an EP where her serum MIC-1 level .1000 ng/
mL. Hence, clinicians could use a serum MIC-1 cut-off, above
which a woman is very unlikely to have an EP, to help determine
which women with PULs can be safely followed up as outpatients.
Furthermore, serum MIC-1 levels were significantly higher in
women with dEPs compared to women with srPULs. Therefore
clinicians could potentially use serum MIC-1 levels in PUL to help
determine which women are likely to require treatment. Both
these approaches, however, would require further validation
before being used in a clinical management algorithm for PUL.
The inability of any single biomarker being able to sensitively
and specifically diagnose EP has led some groups to combine
serum biomarkers in an attempt to improve diagnostic accuracy.
In particular, Rausch notes that biomarkers with varied biological
actions seem to perform best together [8]. This reflects an attempt
to identify numerous deviations in physiological processes com-
mon to both intrauterine and ectopic pregnancy, the sum of which
may allow a combined biomarker panel to predict location. To
date, the best combination of biomarkers (progesterone, vascular
endothelial growth factor (VEGF), inhibin A and activin A) has
achieved a sensitivity of 98% and a specificity of 100%, but only in
42% of the cohort that was able to be characterised [14]. This
panel of biomarkers still requires external validation in a
prospective cohort to determine its clinical viability.
MIC-1, Placental Growth Factor (PlGF) and fms-related
tyrosine kinase 1 (flt1) levels are all lower in EP compared to
dVIUP and higher compared to dNVIUP, [15,16] however, their
reported test performance as single biomarkers for the diagnosis of
EP are difficult to compare due to different cut-offs and outcome
Figure 1. Serum MIC-1 levels in women at first presentation
with a PUL, categorised according to final pregnancy outcome.
Serum MIC-1 levels .1000 ng/mL exclude EP.
doi:10.1371/journal.pone.0066339.g001
Figure 2. ROC Curve analyses of MIC-1 as a biomarker of EP. A)
Comparing MIC-1 levels in women with EP (dEP and pEP) compared to
all other pregnancy outcomes. B) Comparing MIC-1 levels in women
with dEP compared to women with a definite non-EP outcome (dVIUP,
dNVIUP, NP), excluding women with ambiguous pregnancy outcomes
(srPUL, tPUL and pEP). C) Comparing MIC-1 levels in women requiring
treatment (dEP, pEP and tPUL) compared to women who did not
(dVIUP, dNVIUP, srPUL and NP).
doi:10.1371/journal.pone.0066339.g002
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groupings used in their assessment [8]. What is apparent though, is
that MIC-1, PlGF and flt1 all correlate with pregnancy viability.
VEGF in comparison, is elevated in EP compared to dVIUP
[14,17], and in terms of biomarker performance, can distinguish
between EP and dVIUP and EP and dNVIUP with 100%
specificity at cut-offs of 200 pg/mL and 174.5 pg/mL, respec-
tively [18,19]. As MIC-1.1000 ng/mL excludes EP and VEGF
.200 pg/mL diagnoses EP, both with 100% specificity, the use of
these two biomarkers in a diagnostic algorithm may prove
clinically useful, provided their physiological relationship is not
simply diametrically opposed. This would require further inves-
tigation.
Previous studies in early pregnancy show a correlation between
low maternal serum MIC-1 levels and non-viable pregnancies
[12,13]. In this study, serum MIC-1 levels were lower in women
with dEP compared to women with dVIUP, consistent with the
likely insufficient trophoblastic invasion of an EP and its limited
viability within the Fallopian tube environment. In contrast, serum
MIC-1 levels were significantly higher in women with dEP
compared to women with a srPUL, suggesting that serum MIC-1
levels can discriminate between a pregnancy that continues to
grow and requires treatment compared to one that is demising.
Furthermore, a correlation was noted between serum MIC-1
and serum hCG levels in women with dVIUPs and dNVIUPS, but
not in any other pregnancy outcome categories. MIC-1 and hCG
were both lower in women with dNVIUPs compared to women
with dVIUPs (P= 0.1 and P,0.02, respectively). This suggests
MIC-1 may be up-regulated in viable pregnancy, to help mediate
an appropriate immune response within the uterine environment.
Hence serum MIC-1 levels in this study continue to correlate with
relative pregnancy viability.
In conclusion, as a single biomarker, a serum MIC-1 level at the
time of TVUS diagnosis of a PUL is not sufficiently discriminatory
to diagnose EP. Serum MIC-1 levels do, however, correlate with
pregnancy viability and may be used as a cut-off for exclusion of
EP and for determination of which women with a PUL will
require treatment. Serum MIC-1 levels may therefore be useful as
part of a management algorithm for PUL and could likely form
part of a multiplex biomarker assay, to assist clinicians in
diagnosing EP.
Materials and Methods
Patient Samples
This study was approved by the Lothian Research Ethics
Committee (LREC 04/S1103/20 and 09/S1103/39). Written,
informed consent was obtained from all participants. Women
presenting with abdominal pain and/or vaginal bleeding after a
positive home pregnancy test and in whom a TVUS was not able
to locate the pregnancy (i.e. PUL) were recruited. Whole blood
was collected from participants and after clotting for 2 hrs at room
temperature, the sera were collected and stored and 280uC in
multiple aliquots. Participants were followed up and their ultimate
pregnancy outcomes classified according to the recent PUL
consensus statement [4].
Ultrasound Assessments
TVUSs were performed using the Toshiba Aplio XG machine
by a team of trained, qualified and experienced sonographers.
MIC-1 ELISA
Sera were assayed using the GDF-15 (MIC-1) Duoset ELISA kit
(R&D systems, Abingdon, UK) according to the manufacturer’s
instructions. Further details and performance parameters are
available from the manufacturer (www.rndsystems.com/pdf/
DY957). The ELISA was performed in one run, with samples
scrambled throughout the plate. The scientist performing the
ELISA was blinded to clinical groupings of samples.
Because current or past infection with Chlamydia trachomatis is
strongly correlated with risk of EP, and MIC-1 is a cytokine whose
expression may be influenced by other inflammatory and/or
infective processes in the body, we also measured participant’s
serum PgP3 antibody titres as a marker of previous C. trachomatis
exposure by ELISA, as previously described [20].
Statistical Analysis
Statistical analysis and ROC curves were generated using Prism
5.0 (GraphPad Software, La Jolla, USA).
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